Please assess the completion status of the following clinical trial:

Trial Title: Polio End-game Strategies - Poliovirus Type 2 Challenge Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Newborn of either gender born healthy with birth weight 2.0 kg or more, with immediate cry, at the study sites (home or health facility births)~* Not planning to travel away during entire the study period (birth-154 days; birth 22 weeks).~* Parents resident of the study area for last 3 month at the time of enrolment~* Parent/guardian provides informed consent~Exclusion Criteria:~* Newborns found acutely ill at the time of enrolment and requiring emergent medical care/hospitalization, birth weight below 2.0 kg, cry \>2 minutes after birth, or family is planning to be absent during the birth - 154 days study period~* Refusal of blood testing and cord blood testing~* Receipt of OPV after birth before eligibility screen~* Newborns with certain medical conditions i.e., syndromic infants, neonate with petechial or purpura (contraindication of intramuscular injections)~* A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in a member of the immediate family - e.g. several early infant deaths, household member on chemotherapy) will render the newborn ineligible for the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Day
- Healthy Volunteers: f

Study Arms:
- IPV (Type: EXPERIMENTAL): IPV at birth, 6 weeks, 10 weeks, 14 weeks, followed by tOPV at 18 and 22 weeks
- bOPV (Type: EXPERIMENTAL): bOPV at birth, 6, 10, and 14 weeks. followed by tOPV at 18 and 22 weeks of age
- bOPV and IPV (Type: EXPERIMENTAL): bOPV at birth, 6, 10 weeks, and IPV+bOPV at 14 weeks, and tOPV at 18 and 22 weeks of age
- bOPV and IPV and IPV2 (Type: EXPERIMENTAL): bOPV at birth, 6, 10 weeks and bOPV+IPV at 14 weeks and tOPV+IPV2 at 18 weeks and tOPV alone at 22 weeks of age
- tOPV (Type: ACTIVE_COMPARATOR): tOPV at birth, 6, 10, 14, 18 and 22 weeks of age

Based on this trial design, predict the completion outcome and termination type (if applicable).